Search InvestCenter

Recent Quotes

My Watchlist

Top Indices

Articles published by CureVac

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

July 05, 2022

CureVac Announces Voting Results of General Meeting

June 22, 2022

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

June 08, 2022

CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen

June 08, 2022

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

May 25, 2022

Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update

May 25, 2022

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

April 28, 2022

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

April 22, 2022

CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

April 21, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

April 11, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

March 30, 2022

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)

March 01, 2022

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

February 10, 2022

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

January 17, 2022

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

November 19, 2021

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

November 18, 2021

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

November 10, 2021

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

October 12, 2021

CureVac Streamlines European Network for mRNA Product Manufacturing

September 14, 2021

CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

August 31, 2021

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

August 30, 2021

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

August 16, 2021

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

August 16, 2021

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

June 30, 2021

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)

June 30, 2021

CureVac Announces Voting Results of General Meeting

June 25, 2021

CureVac Provides Supervisory Board Update

June 23, 2021

CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV

June 16, 2021

CureVac Appoints Klaus Edvardsen as Chief Development Officer

June 02, 2021

CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

May 28, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.